Immunotherapy response and resistance in patients with advanced uveal melanoma: a retrospective cohort study.
Humans
Uveal Neoplasms
/ pathology
Melanoma
/ drug therapy
Retrospective Studies
Male
Female
Middle Aged
Aged
Nivolumab
/ therapeutic use
Ipilimumab
/ therapeutic use
Immunotherapy
/ methods
Adult
Treatment Outcome
Drug Resistance, Neoplasm
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Progression-Free Survival
Immune checkpoint inhibitors
Immunotherapy
Tebentafusp
Uveal melanoma
Journal
Clinical and experimental medicine
ISSN: 1591-9528
Titre abrégé: Clin Exp Med
Pays: Italy
ID NLM: 100973405
Informations de publication
Date de publication:
01 Oct 2024
01 Oct 2024
Historique:
received:
03
06
2024
accepted:
24
09
2024
medline:
1
10
2024
pubmed:
1
10
2024
entrez:
1
10
2024
Statut:
epublish
Résumé
Metastatic uveal melanoma (mUM) is associated with poor prognosis. Ipilimumab/nivolumab has shown antitumor efficacy in phase II studies. Tebentafusp resulted in longer overall survival (OS) compared to investigator`s choice in a phase III study. We sought to describe the radiological response patterns of mUM patients treated with immunotherapy. Patients with mUM treated with ipilimumab/nivolumab and tebentafusp between July 2018 and December 2022, with available radiological assessment per RECISTv1.1 and/or imPERCIST5, were retrospectively identified and included. Progression-free survival (PFS) and OS rates, liver-specific response and pathological assessment in available liver biopsies were evaluated. In the ipilimumab/nivolumab group, median PFS (mPFS) was 2.9 months (95% CI 2.2-28.6) and mOS 28.9 months (95% CI 12.7-NR). Complete (CMR) and partial (PMR) metabolic response per imPERCIST5, and partial response (PR) per RECISTv1.1 were associated with longer PFS and OS by trend, compared to morphologically and metabolically stable or progressive disease. In the tebentafusp group, mPFS was 2.7 months (95% CI 2.2-3) and mOS 18.6 months (95% CI 11.5-NR). PMR and PR were associated with longer PFS by trend. In both treatments, the overall treatment response was associated with the radiological response at the liver site. In available liver tumor biopsies, differences in pathological and radiological responses were noted. ImPERCIST5 and RECIST v1.1 are valuable tools in the radiological response assessment, but both methods display limitations. Accurate biomarkers to stratify patients at risk for disease progression and future translational studies to investigate mechanisms of response and resistance are required.
Identifiants
pubmed: 39352553
doi: 10.1007/s10238-024-01497-8
pii: 10.1007/s10238-024-01497-8
doi:
Substances chimiques
Nivolumab
31YO63LBSN
Ipilimumab
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
234Informations de copyright
© 2024. The Author(s).
Références
Harbour JW. The genetics of uveal melanoma: an emerging framework for targeted therapy. Pigment Cell Melanoma Res. 2012;25(2):171–81.
pubmed: 22268848
pmcid: 4470256
doi: 10.1111/j.1755-148X.2012.00979.x
Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology. 2011;118(9):1881–5.
pubmed: 21704381
doi: 10.1016/j.ophtha.2011.01.040
Virgili G, Gatta G, Ciccolallo L, Capocaccia R, Biggeri A, Crocetti E, et al. Incidence of uveal melanoma in Europe. Ophthalmology. 2007;114(12):2309–15.
pubmed: 17498805
doi: 10.1016/j.ophtha.2007.01.032
Stang A, Parkin DM, Ferlay J, Jockel KH. International uveal melanoma incidence trends in view of a decreasing proportion of morphological verification. Int J Cancer. 2005;114(1):114–23.
pubmed: 15523698
doi: 10.1002/ijc.20690
Augsburger JJ, Correa ZM, Shaikh AH. Effectiveness of treatments for metastatic uveal melanoma. Am J Ophthalmol. 2009;148(1):119–27.
pubmed: 19375060
doi: 10.1016/j.ajo.2009.01.023
Rantala ES, Hernberg M, Kivela TT. Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis. Melanoma Res. 2019;29(6):561–8.
pubmed: 30664106
pmcid: 6887637
doi: 10.1097/CMR.0000000000000575
Caminal JM, Ribes J, Cleries R, Ibanez N, Arias L, Piulats JM, et al. Relative survival of patients with uveal melanoma managed in a single center. Melanoma Res. 2012;22(3):271–7.
pubmed: 22516965
doi: 10.1097/CMR.0b013e328353ef30
Vergara IA, Wilmott JS, Long GV, Scolyer RA. Genetic drivers of non-cutaneous melanomas: challenges and opportunities in a heterogeneous landscape. Exp Dermatol. 2022;31(1):13–30.
pubmed: 33455025
doi: 10.1111/exd.14287
Van Raamsdonk CD, Bezrookove V, Green G, Bauer J, Gaugler L, O’Brien JM, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature. 2009;457(7229):599–602.
pubmed: 19078957
doi: 10.1038/nature07586
Harbour JW, Onken MD, Roberson ED, Duan S, Cao L, Worley LA, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science. 2010;330(6009):1410–3.
pubmed: 21051595
pmcid: 3087380
doi: 10.1126/science.1194472
Qin Y, Bollin K, de Macedo MP, Carapeto F, Kim KB, Roszik J, et al. Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapy. J Immunother Cancer. 2020;8(2):e000960.
pubmed: 33203661
pmcid: 7674090
doi: 10.1136/jitc-2020-000960
Hoefsmit EP, Rozeman EA, Van TM, Dimitriadis P, Krijgsman O, Conway JW, et al. Comprehensive analysis of cutaneous and uveal melanoma liver metastases. J Immunother Cancer. 2020;8(2):e001501.
pubmed: 33262254
pmcid: 7713183
doi: 10.1136/jitc-2020-001501
Krishna Y, McCarthy C, Kalirai H, Coupland SE. Inflammatory cell infiltrates in advanced metastatic uveal melanoma. Hum Pathol. 2017;66:159–66.
pubmed: 28655639
doi: 10.1016/j.humpath.2017.06.005
Zimmer L, Vaubel J, Mohr P, Hauschild A, Utikal J, Simon J, et al. Phase II DeCOG-study of ipilimumab in pretreated and treatment-naive patients with metastatic uveal melanoma. PLoS ONE. 2015;10(3): e0118564.
pubmed: 25761109
pmcid: 4356548
doi: 10.1371/journal.pone.0118564
Algazi AP, Tsai KK, Shoushtari AN, Munhoz RR, Eroglu Z, Piulats JM, et al. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. Cancer. 2016;122(21):3344–53.
pubmed: 27533448
doi: 10.1002/cncr.30258
Pelster MS, Gruschkus SK, Bassett R, Gombos DS, Shephard M, Posada L, et al. Nivolumab and ipilimumab in metastatic uveal melanoma: results from a single-arm phase II study. J Clin Oncol. 2021;39(6):599–607.
pubmed: 33125309
doi: 10.1200/JCO.20.00605
Piulats JM, Espinosa E, de la Cruz ML, Varela M, Alonso Carrion L, Martin-Algarra S, et al. Nivolumab plus ipilimumab for treatment-naive metastatic uveal melanoma: an open-label, multicenter, phase ii trial by the Spanish multidisciplinary melanoma group (GEM-1402). J Clin Oncol. 2021;39(6):586–98.
pubmed: 33417511
doi: 10.1200/JCO.20.00550
Nathan P, Hassel JC, Rutkowski P, Baurain JF, Butler MO, Schlaak M, et al. Overall survival benefit with tebentafusp in metastatic uveal melanoma. N Engl J Med. 2021;385(13):1196–206.
pubmed: 34551229
doi: 10.1056/NEJMoa2103485
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.
pubmed: 19097774
doi: 10.1016/j.ejca.2008.10.026
Lopci E, Hicks RJ, Dimitrakopoulou-Strauss A, Dercle L, Iravani A, Seban RD, et al. Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [(18)F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0. Eur J Nucl Med Mol Imaging. 2022;49(7):2323–41.
pubmed: 35376991
pmcid: 9165250
doi: 10.1007/s00259-022-05780-2
Ito K, Teng R, Schoder H, Humm JL, Ni A, Michaud L, et al. (18)F-FDG PET/CT for Monitoring of Ipilimumab therapy in patients with metastatic melanoma. J Nucl Med. 2019;60(3):335–41.
pubmed: 30413661
pmcid: 6424231
doi: 10.2967/jnumed.118.213652
Blomen CL, Kott J, Hartung TI, Torster LK, Gebhardt C. Combination of immune checkpoint inhibitors and liver-specific therapies in liver-metastatic uveal melanoma: can we thus overcome its high resistance. Cancers (Basel). 2021;13(24):6390.
pubmed: 34945010
doi: 10.3390/cancers13246390
Tomsitz D, Ruf T, Heppt M, Staeger R, Ramelyte E, Dummer R, et al. Tebentafusp in patients with metastatic uveal melanoma: a real-life retrospective multicenter study. Cancers (Basel). 2023;15(13):3430.
pubmed: 37444540
doi: 10.3390/cancers15133430
Pandiani C, Strub T, Nottet N, Cheli Y, Gambi G, Bille K, et al. Single-cell RNA sequencing reveals intratumoral heterogeneity in primary uveal melanomas and identifies HES6 as a driver of the metastatic disease. Cell Death Differ. 2021;28(6):1990–2000.
pubmed: 33462406
pmcid: 8185008
doi: 10.1038/s41418-020-00730-7
Lin W, Beasley AB, Ardakani NM, Denisenko E, Calapre L, Jones M, et al. Intra- and intertumoral heterogeneity of liver metastases in a patient with uveal melanoma revealed by single-cell RNA sequencing. Cold Spring Harb Mol Case Stud. 2021;7(5):a006111.
pubmed: 34470851
pmcid: 8559622
doi: 10.1101/mcs.a006111
Damato BE, Dukes J, Goodall H, Carvajal RD. Tebentafusp: T cell redirection for the treatment of metastatic uveal melanoma. Cancers (Basel). 2019;11(7):971.
pubmed: 31336704
doi: 10.3390/cancers11070971
Goebeler ME, Bargou RC. T cell-engaging therapies-BiTEs and beyond. Nat Rev Clin Oncol. 2020;17(7):418–34.
pubmed: 32242094
doi: 10.1038/s41571-020-0347-5
Carter BW, Murthy R, Balmes G, Wachter EA, Patel S. Response assessment of metastatic uveal melanoma treated with rose Bengal disodium. Ann Oncol. 2019;30:xi46.
doi: 10.1093/annonc/mdz451.033
Ramtohul T, Abdul-Baki M, Rodrigues M, Cassoux N, Gardrat S, Ait Rais K, et al. Tumor growth rate as a predictive marker for recurrence and survival after liver resection in patients with liver metastases of uveal melanoma. Ann Surg Oncol. 2022;29(13):8480–91.
pubmed: 35980554
doi: 10.1245/s10434-022-12368-5
Carvajal RD, Butler MO, Shoushtari AN, Hassel JC, Ikeguchi A, Hernandez-Aya L, et al. Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial. Nat Med. 2022;28(11):2364–73.
pubmed: 36229663
pmcid: 9671803
doi: 10.1038/s41591-022-02015-7
Sullivan RJ, Collins L, Sacco JJ, Thiyagarajah P, Nathan PD, Carvajal RD. Use of baseline and serial ctDNA dynamics to predict outcomes in patients treated with first-line tebentafusp, including those who were and were not treated beyond progression. J Clinic Oncol. 2024;42(16_suppl):9536–9536.
doi: 10.1200/JCO.2024.42.16_suppl.9536
Feng D, Collins L, Callahan MK, Sullivan RJ, Piperno-Neumann S, Nathan PD, et al. Early ctDNA reduction may identify patients with stable disease and long OS on tebentafusp. J Clinic Oncol. 2023;41(16_suppl):9589–9589.
doi: 10.1200/JCO.2023.41.16_suppl.9589
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381(16):1535–46.
pubmed: 31562797
doi: 10.1056/NEJMoa1910836
Nishino M. Tumor response assessment for precision cancer therapy: response evaluation criteria in solid tumors and beyond. Am Soc Clin Oncol Educ Book. 2018;38:1019–29.
pubmed: 30231378
doi: 10.1200/EDBK_201441
Dimitriou F, Lo SN, Tan AC, Emmett L, Kapoor R, Carlino MS, et al. FDG-PET to predict long-term outcome from anti-PD-1 therapy in metastatic melanoma. Ann Oncol. 2022;33(1):99–106.
pubmed: 34687894
doi: 10.1016/j.annonc.2021.10.003
Pires da Silva I, Lo S, Quek C, Gonzalez M, Carlino MS, Long GV, Menzies AM. Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti-PD-1 therapy. Cancer. 2020;126(1):86–97.
pubmed: 31584722
doi: 10.1002/cncr.32522
Dimitriou F, Frauchiger AL, Urosevic-Maiwald M, Naegeli MC, Goldinger SM, Barysch M, et al. Sarcoid-like reactions in patients receiving modern melanoma treatment. Melanoma Res. 2018;28(3):230–6.
pubmed: 29485531
pmcid: 5929490
doi: 10.1097/CMR.0000000000000437
Park HJ, Kim KW, Pyo J, Suh CH, Yoon S, Hatabu H, Nishino M. Incidence of pseudoprogression during immune checkpoint inhibitor therapy for solid tumors: a systematic review and meta-analysis. Radiology. 2020;297(1):87–96.
pubmed: 32749204
doi: 10.1148/radiol.2020200443
Frelaut M, du Rusquec P, de Moura A, Le Tourneau C, Borcoman E. Pseudoprogression and hyperprogression as new forms of response to immunotherapy. BioDrugs. 2020;34(4):463–76.
pubmed: 32394415
doi: 10.1007/s40259-020-00425-y
Li Y, Flavell RR, Juarez R, Chow M, Wu C, Tsai K, et al. Retrospective study of the incidence of sarcoidosis-like reaction in patients treated with immunotherapy. Clin Radiol. 2023;78(2):e131–6.
pubmed: 36344282
doi: 10.1016/j.crad.2022.09.127
Kelly D, Rose AAN, Muniz TP, Hogg D, Butler MO, Saibil SD, et al. Development of a metastatic uveal melanoma prognostic score (MUMPS) for use in patients receiving immune checkpoint inhibitors. Cancers (Basel). 2021;13(14):3640.
pubmed: 34298857
doi: 10.3390/cancers13143640
Kubota R, Kubota K, Yamada S, Tada M, Ido T, Tamahashi N. Microautoradiographic study for the differentiation of intratumoral macrophages, granulation tissues and cancer cells by the dynamics of fluorine-18-fluorodeoxyglucose uptake. J Nucl Med. 1994;35(1):104–12.
pubmed: 8271030
Beuthien-Baumann B, Sachpekidis C, Gnirs R, Sedlaczek O. Adapting imaging protocols for PET-CT and PET-MRI for immunotherapy monitoring. Cancers (Basel). 2021;13(23):6019.
pubmed: 34885129
doi: 10.3390/cancers13236019